Literature DB >> 23172884

Variation in precursor lesions of pancreatic cancer among high-risk groups.

Thomas P Potjer1, Ingrid Schot, Peter Langer, Johannes T Heverhagen, Martin N J M Wasser, Emily P Slater, Günter Klöppel, Hans M Morreau, Bert A Bonsing, Wouter H de Vos Tot Nederveen Cappel, Mathias Bargello, Thomas M Gress, Hans F A Vasen, Detlef K Bartsch.   

Abstract

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) surveillance programs are currently offered to high-risk individuals aiming to detect precursor lesions or PDAC at an early stage. We assessed differences in frequency and behavior of precursor lesions and PDAC between two high-risk groups. EXPERIMENTAL
DESIGN: Individuals with a p16-Leiden germline mutation (N = 116; median age 54 years) and individuals from familial pancreatic cancer (FPC) families (N = 125; median age 47 years) were offered annual surveillance by MRI and magnetic resonance cholangiopancreatography (MRCP) with or without endoscopic ultrasound (EUS) for a median surveillance period of 34 months (0-127 months) or 36 months (0-110 months), respectively. Detailed information was collected on pancreatic cystic lesions detected on MRCP and precursor lesions in surgical specimens of patients who underwent pancreatic surgery.
RESULTS: Cystic lesions were more common in the FPC cohort (42% vs. 16% in p16-Leiden cohort), whereas PDAC was more common in the p16-Leiden cohort (7% vs. 0.8% in FPC cohort). Intraductal papillary mucinous neoplasm (IPMN) was a common finding in surgical specimens of FPC-individuals, and was only found in two patients of the p16-Leiden cohort. In the p16-Leiden cohort, a substantial proportion of cystic lesions showed growth or malignant transformation during follow-up, whereas in FPC individuals most cystic lesions remain stable.
CONCLUSION: In p16-Leiden mutation carriers, cystic lesions have a higher malignant potential than in FPC-individuals. On the basis of these findings, a more intensive surveillance program may be considered in this high-risk group. ©2012 AACR

Entities:  

Mesh:

Year:  2012        PMID: 23172884     DOI: 10.1158/1078-0432.CCR-12-2730

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

Review 1.  Early detection and prevention of pancreatic cancer: is it really possible today?

Authors:  Marco Del Chiaro; Ralf Segersvärd; Matthias Lohr; Caroline Verbeke
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

2.  Is intraductal tubulopapillary neoplasia a new entity in the spectrum of familial pancreatic cancer syndrome?

Authors:  Marco Del Chiaro; Raffaella Pozzi Mucelli; John Blomberg; Ralf Segersvärd; Caroline Verbeke
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

Review 3.  Progress report: familial pancreatic cancer.

Authors:  Ioannis Mintziras; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

Review 4.  Surveillance for neoplasia in the pancreas.

Authors:  Kasper A Overbeek; Djuna L Cahen; Marcia Irene Canto; Marco J Bruno
Journal:  Best Pract Res Clin Gastroenterol       Date:  2016-11-05       Impact factor: 3.043

5.  A histomorphologic comparison of familial and sporadic pancreatic cancers.

Authors:  Alison P Klein; Ralph H Hruban; Aatur D Singhi; Hiroyuki Ishida; Syed Z Ali; Michael Goggins; Marcia Canto; Christopher Wolfgang; Zina Meriden; Nicholas Roberts
Journal:  Pancreatology       Date:  2015-04-23       Impact factor: 3.996

Review 6.  Screening for pancreatic cancer in familial high-risk individuals: A systematic review.

Authors:  Chao Lu; Cheng-Fu Xu; Xing-Yong Wan; Hua-Tuo Zhu; Chao-Hui Yu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

7.  Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals.

Authors:  Gabriele Capurso; Marianna Signoretti; Roberto Valente; Urban Arnelo; Matthias Lohr; Jan-Werner Poley; Gianfranco Delle Fave; Marco Del Chiaro
Journal:  World J Gastrointest Endosc       Date:  2015-07-25

8.  Development of a high risk pancreatic screening clinic using 3.0 T MRI.

Authors:  Chad A Barnes; Elizabeth Krzywda; Shannon Lahiff; Dena McDowell; Kathleen K Christians; Paul Knechtges; Parag Tolat; Mark Hohenwalter; Kulwinder Dua; Abdul H Khan; Douglas B Evans; Jennifer Geurts; Susan Tsai
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

Review 9.  Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis.

Authors:  Marianna Signoretti; Marco J Bruno; Giulia Zerboni; Jan-Werner Poley; Gianfranco Delle Fave; Gabriele Capurso
Journal:  United European Gastroenterol J       Date:  2018-01-08       Impact factor: 4.623

10.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.